Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218346

SCHEMBL23218346

SCHEMBL23218346

CCOC(=O)Cc1ccccc1OCc1c(C(O)C(F)(F)F)oc2ccc(Br)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBXAS1 P24557 1/20 0.36
▸ ALOX5 P09917 5/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ TSHR P16473 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ MAPT P10636 3/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CFD P00746 1/20 0.34
▸ TP53 P04637 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PTGFR P43088 1/20 0.33
▸ CCNB2 O95067 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ CCNB1 P14635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853047 0.89 TBXAS1 (0.39) TBXAS1ALOX5CA12CA9TSHR
SCHEMBL23218746 0.89 TBXAS1 (0.39) TBXAS1ALOX5CA12CA9TSHR
SCHEMBL29852884 0.89 TBXAS1 (0.39) TBXAS1ALOX5CA12CA9TSHR
SCHEMBL23218087 0.89 TBXAS1 (0.39) TBXAS1ALOX5CA12CA9TSHR
SCHEMBL23218378 0.88 TSHR (0.38) ALOX5CA12CA9TSHRLMNA
SCHEMBL29853132 0.88 TBXAS1 (0.39) TBXAS1ALOX5CA12CA9TSHR
SCHEMBL23218833 0.88 TBXAS1 (0.39) TBXAS1ALOX5CA12CA9TSHR
SCHEMBL29852960 0.85 ALOX5 (0.41) TBXAS1ALOX5CA12CA9TSHR
SCHEMBL23218988 0.85 ALOX5 (0.41) TBXAS1ALOX5CA12CA9TSHR
SCHEMBL23219259 0.85 TBXAS1 (0.41) TBXAS1ALOX5CA12CA9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TBXAS1 963/4885ALOX5 317/4885CA12 1610/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 392/4885ALOX5 260/4885CA12 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.